Enveric Biosciences Expands IP Portfolio With New U.S. Patent For Novel Carboxylated Psilocybin Derivatives Supporting Its EVM301 Series Of Drug Candidates
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences (NASDAQ:ENVB) has been granted a new U.S. patent for its EVM301 Series of drug candidates, which are carboxylated psilocybin derivatives aimed at treating mental health disorders. The patent covers novel compositions and pharmaceutical drug formulations, and is expected to strengthen and add value to Enveric's EVM301 Series. The company's CEO believes this could greatly enhance the commercial opportunity of EVM301 Series-based therapies.
September 20, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has secured a new patent for its EVM301 Series of drug candidates, which could enhance their commercial viability and value.
The new patent provides Enveric with exclusive rights to novel compositions and pharmaceutical drug formulations for its EVM301 Series. This could potentially increase the commercial value of these drug candidates, as it strengthens the company's intellectual property portfolio and could deter competition. This could positively impact Enveric's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100